Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCULATIONAHA.118.038482 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety of a short-term infusion of fosnetupitant in patients with gastrointestinal and breast cancer: a prospective study.
Oncologist
September 2024
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi 484-8681, Japan.
Article Synopsis
- Fosnetupitant is an anti-nausea medication used for patients undergoing chemotherapy, showing non-inferiority to another treatment in prior studies.
- A phase II study evaluated the safety of a faster 15-minute infusion of fosnetupitant in cancer patients, focusing on allergic reaction incidents and other side effects.
- Results indicated that the 15-minute infusion was safe, with no allergic reactions or severe side effects reported, and a high complete response rate of 87%.
Chronic intermittent hypoxia triggers cardiac fibrosis: Role of epididymal white adipose tissue senescent remodeling?
Acta Physiol (Oxf)
November 2024
Université Grenoble Alpes, INSERM U1300, CHU Grenoble Alpes, HP2, Grenoble, France.
Article Synopsis
- Obstructive sleep apnea (OSA) impacts nearly 1 billion people globally, causing chronic intermittent hypoxia (CIH) that leads to organ damage, especially affecting the heart and visceral white adipose tissue (WAT).
- The study aimed to explore if CIH causes premature senescence in visceral WAT, which in turn may trigger changes in heart structure and function.
- Results showed that CIH caused significant changes in WAT and early signs of heart damage, but these effects could be mitigated through surgical removal of fat tissue or deletion of specific genes, highlighting visceral WAT senescence as a promising target for combating OSA-related issues.
Purpose: We aimed to develop a simulation program for physicians and nurses involved in virtual reality (VR) and augmented reality (AR) treatment and care from the perspective of these professionals and older adults with dementia who developed delirium, and to test the effectiveness of the program.
Methods: effectiveness of the program was analyzed through free-response statements from 67 nurses (84.8%) and 12 doctors (15.
Comparison of proportions and prognostic impact of pathological complete response between evaluations of representative specimen and total specimen in primary breast cancer after neoadjuvant chemoradiotherapy: an ancillary study of JCOG0306.
Breast Cancer Res Treat
November 2024
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Article Synopsis
- The JCOG0306 trial studied the effectiveness of neoadjuvant chemotherapy followed by radiation therapy in primary breast cancer, comparing the representative specimen (RS) method to the traditional total specimen (TS) method for evaluating pathological complete response (pCR).
- The study involved 103 patients, assessing pCR and quasi-pCR rates with both methods, and found that RS had a higher concordance rate with better identification of strong prognostic groups.
- Results indicated that both RS and TS methods provided similar prognostic outcomes for pCR groups, but RS method had significant advantages in differentiating patient survival rates more effectively than TS.
Pilot trial of an electronic patient-reported outcome monitoring system in patients with metastatic breast cancer undergoing chemotherapy.
Breast Cancer
March 2024
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Background: Electronic patient-reported outcomes monitoring (ePROM) is a useful communication tool for patients and healthcare providers in cancer chemotherapy. In this study, we examined the feasibility of our newly developed ePROM system, which we refer to as "Hibilog".
Methods: An ePROM app was developed by extracting 18 items from the Patient-Reported Outcome-Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!